» Articles » PMID: 35515788

Tumor Microenvironment Triggered Biodegradation of Inorganic Nanoparticles for Enhanced Tumor Theranostics

Overview
Journal RSC Adv
Specialty Chemistry
Date 2022 May 6
PMID 35515788
Authors
Affiliations
Soon will be listed here.
Abstract

Inorganic nanoparticles (NPs)-mediated tumor theranostics have attracted widespread attention due to their unique physicochemical properties, such as optical, electrical, magnetic, and thermal properties. In the past decade, great advancements have been made in inorganic NPs-associated drug delivery, multimodal tumor imaging, and tumor therapy. However, the potential toxicity of inorganic NPs due to their low biodegradability, background signals interference and treatment side effects limit their clinical application. Therefore, developing biodegradable and intelligent NPs is beneficial to avoid excessive metal ions deposition, specific tumor imaging and treatment. In this review, we summarize the recent advances in tumor microenvironment (TME)-triggered biodegradation of inorganic NPs accompanied by imaging signal amplification and the released ions-mediated tumor therapy. First, the feature characteristics of the TME are introduced, including mild acidity, hypoxia, overexpressed reactive oxygen species (ROS), glutathione (GSH), and enzymes ; then, the biodegradation of NPs in a TME-induced activation of imaging signals, such as magnetic resonance (MR) imaging and fluorescence imaging is described; furthermore, tumor therapies through "Fenton", "Fenton-like" reactions, and interference of biological effects in cells is presented. Finally, the challenges and outlook for improving the degradation efficiency, imaging, specificity and efficiency of tumor imaging and treatment are discussed.

Citing Articles

Nanotechnology-based non-viral vectors for gene delivery in cardiovascular diseases.

Jiao L, Sun Z, Sun Z, Liu J, Deng G, Wang X Front Bioeng Biotechnol. 2024; 12:1349077.

PMID: 38303912 PMC: 10830866. DOI: 10.3389/fbioe.2024.1349077.


Research progress of nanovaccine in anti-tumor immunotherapy.

Yao M, Liu X, Qian Z, Fan D, Sun X, Zhong L Front Oncol. 2023; 13:1211262.

PMID: 37692854 PMC: 10484753. DOI: 10.3389/fonc.2023.1211262.


Effects of morphology and size of nanoscale drug carriers on cellular uptake and internalization process: a review.

Zhang W, Taheri-Ledari R, Ganjali F, Mirmohammadi S, Qazi F, Saeidirad M RSC Adv. 2023; 13(1):80-114.

PMID: 36605676 PMC: 9764328. DOI: 10.1039/d2ra06888e.


The potential of oxygen and nitrogen species-regulating drug delivery systems in medicine.

Soltan M, Bartusik-Aebisher D, Aebisher D Front Bioeng Biotechnol. 2022; 10:973080.

PMID: 36110312 PMC: 9468659. DOI: 10.3389/fbioe.2022.973080.

References
1.
Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

2.
Rhyner M, Smith A, Gao X, Mao H, Yang L, Nie S . Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine (Lond). 2007; 1(2):209-17. DOI: 10.2217/17435889.1.2.209. View

3.
Reichel D, Tripathi M, Butte P, Saouaf R, Perez J . Tumor-Activatable Clinical Nanoprobe for Cancer Imaging. Nanotheranostics. 2019; 3(2):196-211. PMC: 6536784. DOI: 10.7150/ntno.34921. View

4.
Ehlerding E, Chen F, Cai W . Biodegradable and Renal Clearable Inorganic Nanoparticles. Adv Sci (Weinh). 2016; 3(2). PMC: 4944857. DOI: 10.1002/advs.201500223. View

5.
Ding B, Zheng P, Ma P, Lin J . Manganese Oxide Nanomaterials: Synthesis, Properties, and Theranostic Applications. Adv Mater. 2020; 32(10):e1905823. DOI: 10.1002/adma.201905823. View